Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2025)

Revolution Medicines has reported Non-Current Deferred Tax Liability over the past 7 years, most recently at $2.4 million for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $2.4 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (changed 0.0% YoY), and the annual figure for FY2025 was $2.4 million, changed 0.0%.
  • Non-Current Deferred Tax Liability for Q4 2025 was $2.4 million at Revolution Medicines, roughly flat from $2.4 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for RVMD hit a ceiling of $7.4 million in Q1 2021 and a floor of $2.4 million in Q4 2024.
  • Median Non-Current Deferred Tax Liability over the past 5 years was $5.1 million (2022), compared with a mean of $5.0 million.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: increased 5.07% in 2021 and later crashed 55.82% in 2023.
  • Revolution Medicines' Non-Current Deferred Tax Liability stood at $7.4 million in 2021, then decreased by 5.63% to $7.0 million in 2022, then plummeted by 55.66% to $3.1 million in 2023, then decreased by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025.
  • The last three reported values for Non-Current Deferred Tax Liability were $2.4 million (Q4 2025), $2.4 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.